Effects of switching from twice-daily to once-daily tacrolimus formulation on quality of life, anxiety, and transplant benefit perception after kidney transplantation

Jacopo Romagnoli, Franco Citterio, Rosaria Calia, Carlo Lai, Paola Aceto, Massimiliano Luciani, Antonio Gargiulo, R. Calia, M. Luciani, S. Lai

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

15 Citazioni (Scopus)

Abstract

This study investigated whether switching from the twice-daily (Prograf; TAC) to the once-daily formulation of tacrolimus with extended release (Advagraf; XL) affected quality of life, anxiety, and transplant benefit perception after allogeneic kidney transplantation.
Lingua originaleEnglish
pagine (da-a)1020-1023
Numero di pagine4
RivistaTransplantation Proceedings
Volume43
DOI
Stato di pubblicazionePubblicato - 2011

Keywords

  • Adult
  • Aged
  • Analysis of Variance
  • Anxiety
  • Delayed-Action Preparations
  • Drug Administration Schedule
  • Drug Monitoring
  • Female
  • Graft Rejection
  • Health Knowledge, Attitudes, Practice
  • Humans
  • Immunosuppressive Agents
  • Italy
  • Kidney Transplantation
  • Male
  • Middle Aged
  • Perception
  • Psychiatric Status Rating Scales
  • Quality of Life
  • Questionnaires
  • Tacrolimus
  • Time Factors
  • Treatment Outcome
  • Truth Disclosure

Fingerprint Entra nei temi di ricerca di 'Effects of switching from twice-daily to once-daily tacrolimus formulation on quality of life, anxiety, and transplant benefit perception after kidney transplantation'. Insieme formano una fingerprint unica.

Cita questo